E-7386
- Generic Name
- E-7386
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
- Conditions
- Carcinoma, HepatocellularMelanomaColorectal Neoplasms
- Interventions
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 89
- Registration Number
- NCT05091346
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Providence Medical Center, Portland, Oregon, United States
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-24
- Lead Sponsor
- Eisai Limited
- Registration Number
- NCT04840927
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
- Conditions
- NeoplasmsLiver NeoplasmsColorectal NeoplasmsEndometrial NeoplasmsCarcinoma, Hepatocellular
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT04008797
- Locations
- 🇫🇷
ICANs, Strasbourg, France
🇫🇷Gustave Roussy Institute (IGR), Villejuif, France
🇮🇹Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche, Ancona, Italy
A Food-Effect Study of E7386 in Healthy Participants
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT03996226
- Locations
- 🇺🇸
PPD, Austin, Texas, United States
A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)
- Conditions
- Gastrointestinal TumorsColorectal NeoplasmsSolid Neoplasms
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03833700
- Locations
- 🇯🇵
Eisai Trial Site#8, Sendai, Miyagi, Japan
🇯🇵Eisai Trial Site #5, Sapporo, Hokkaido, Japan
🇯🇵Eisai Trial Site #4, Fukuoka, Japan
Study of E7386 in Participants With Selected Advanced Neoplasms
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03264664
- Locations
- 🇬🇧
Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇺🇸Mayo Clinic Comprehensive Caner, Rochester, Minnesota, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.